Chameleon Biosciences

About This Project

Chameleon Biosciences is transforming gene therapy with a re-dosable, AAV based gene therapy. Our two base technologies, Effector Vectors and Exo-AAV, are not constrained by the same immune system limitations that prevent more widespread use of current AAV gene therapies. Chameleon is committed to treating greater numbers of patients suffering from rare diseases with disease-correcting genetic medicines administered as many times as needed.



Fall 2018


Fall 2018